The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | Recent developments in SCLC
Misty Shields, MD, PhD, Indiana University, Bloomington, IN, discusses recent strategies and novel therapies for small cell lung cancer (SCLC). Current studies demonstrate promise for second and third-line therapies, including bispecific T-cell engagers (BITEs) such as tarlatamab. Dr Shields also comments on new data on SCLC relapse in heavily pre-treated patients. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
